CN1294149C - 一种能特异杀死肿瘤细胞的基因工程重组蛋白 - Google Patents

一种能特异杀死肿瘤细胞的基因工程重组蛋白 Download PDF

Info

Publication number
CN1294149C
CN1294149C CN 03137587 CN03137587A CN1294149C CN 1294149 C CN1294149 C CN 1294149C CN 03137587 CN03137587 CN 03137587 CN 03137587 A CN03137587 A CN 03137587A CN 1294149 C CN1294149 C CN 1294149C
Authority
CN
China
Prior art keywords
ala
leu
gly
glu
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN 03137587
Other languages
English (en)
Other versions
CN1566159A (zh
Inventor
聂李亚
马素永
文美玉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Northland Biotech Co Ltd
Original Assignee
Beijing Northland Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Northland Biotech Co Ltd filed Critical Beijing Northland Biotech Co Ltd
Priority to CN 03137587 priority Critical patent/CN1294149C/zh
Publication of CN1566159A publication Critical patent/CN1566159A/zh
Application granted granted Critical
Publication of CN1294149C publication Critical patent/CN1294149C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Abstract

本专利涉及一种能特异杀死肿瘤细胞的蛋白质，经过基因工程改造以后，杀伤肿瘤细胞的活性大大增强，在肿瘤治疗方面有着很大药用潜力。

Description

一种能特异杀死肿瘤细胞的基因工程重组蛋白
一.技术领域
癌症是目前严重威胁人们健康的一种疾病，据报道，全球每年癌症新发病人约1000万，我国每年新发癌症患者近100万，死亡约150万。目前对癌症治疗并没有非常有效的方法，如果早期发现可以使用手术，但大部分是在后期发现，只能通过放疗或化疗来进行治疗。放疗法一般使用阿霉素等药物，具有很大的副作用，主要有骨髓抑制而造成的各种血相降低，胃肠道反应，脱发，肝功能损伤和神经系统损伤等。而放疗的副作用更大，给病人带来巨大的痛苦。并且放化疗的有效率也不高，在30％左右。
鉴于此，急需找到一种副作用小并且有效率高的方法来对癌症进行治疗，随着现代生物技术的不断发展，这种方法成为了可能：由于放化疗副作用大的一个十分重要的原因是其毒性缺乏选择性，其在杀伤癌症细胞的同时也大量地杀伤了正常细胞，而生物导向技术有望解决这个问题，选用一些导向分子，如特异表达受体的配体或者受体的特异性抗体等来作为导向，连接上毒素，即是生物靶向药物，可以靶向的到达肿瘤部位，选择性地杀伤肿瘤细胞，达到治疗肿瘤的同时毒性很小的目的。
二.背景技术
关于生物靶向性药物，目前的导向分子有人促黄体生成激素释放因子(LHRH)，表皮生长因子(EGF)和白细胞介素2等，其中LHRH仅有10个氨基酸组成，分子量小，融合后不会影响毒素蛋白的空间构象，关于毒素部分，可选的有假单胞菌外毒素A(PE)，白喉毒素，蓖麻毒素等，目前较常见的是假单胞菌外毒素A(PE)，PE是一个由613个氨基酸组成的蛋白分子，去掉N末端1-252位氨基酸后就成为了PE40分子，由于分子量的减少，PE40成为一个常用的毒素。目前有报道的生物靶向性药物有白细胞介素2-白喉毒素，表皮生长因子-白喉毒素和LHRH-PE40，特异抗体连接细胞毒素等，但是该类毒素的临床用量较大，导致副作用较大，所以截止目前为止，生物靶向性药物只有白细胞介素2-白喉毒素在美国上市，而其他种类的药物还处于临床或临床前阶段，本专利针对生物靶向性药物效价低、用量大的特点，研究了一系列的生物导向融合蛋白，其具有生物活性高，用量小的特点。
三.发明内容
本专利主要是研究LHRH-PE40系列融合蛋白的基因工程改造，从而提高其杀伤癌细胞的生物活性，我们主要从以下2方面进行改造：1.对融合蛋白的LHRH部分进行改造，增强其与癌细胞结合能力；2.对融合蛋白的细胞毒素PE40部分进行改造，增强其癌细胞杀伤能力；3同时对融合蛋白的LHRH和PE40两方面进行改造，增强其癌细胞杀伤能力，从而达到减少用药量，降低体内毒副反应，延缓抗体产生时间，降低生产成本，增强治疗效果的目的，具有广阔的临床效益和社会效益。
LHRH作为融合蛋白导向部分氨基酸序列为：
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly
LHRH突变体氨基酸序列分别为：
Glu-His-Trp-Ser-Tyr-Ala-Leu-Arg-Pro-Gly
Glu-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly
Glu-His-Trp-Ser-Tyr-Leu-Leu-Arg-Pro-Gly
假单胞杆菌外毒素A PE40作为融合蛋白毒素部分氨基酸序列为
253-279
Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg
280-300
Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala
301-330
Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg
331-364
Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn
365-399
Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu
400-613
Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys
(一).首先对融合蛋白假单胞杆菌外毒素A部分进行改造：
1.本专利对假单胞杆菌外毒素A PE40(氨基酸253-613)进行缺失替换突变，缺失替换其C末端5个氨基酸即609-613位氨基酸REDLK置换为XYEL，其中X代表赖氨酸或精氨酸，Y代表天冬氨酸，谷氨酰胺或谷氨酸，E代表谷氨酸，L代表亮氨酸。
2.本专利对假单胞杆菌外毒素A PE40进行缺失突变，缺失其N末端氨基酸253-279及氨基酸365-380部分，取其氨基酸280-364和氨基酸381-613部分按原顺序首尾相连得到蛋白即为PE35。
3.本专利对PE35C末端5个氨基酸REDLK置换为XYEL，其中X代表赖氨酸或精氨酸，Y代表天冬氨酸，谷氨酰胺或谷氨酸，E代表谷氨酸，L代表亮氨酸。
4.本专利取假单胞杆菌外毒素A缺失氨基酸365-380部分，取其氨基酸253-364和氨基酸381-613部分按原顺序首尾相连得到蛋白即为PE38。
5.本专利对PE38C末端5个氨基酸REDLK置换为XYEL，其中X代表赖氨酸或精氨酸，Y代表天冬氨酸，谷氨酰胺或谷氨酸，E代表谷氨酸，L代表亮氨酸。
6.本专利取假单胞杆菌外毒素A缺失氨基酸253-279部分，取其氨基酸280-613部分得到蛋白即为PE37。
7.本专利对PE37C末端5个氨基酸REDLK置换为XYEL，其中X代表赖氨酸或精氨酸，Y代表天冬氨酸，谷氨酰胺或谷氨酸，E代表谷氨酸，L代表亮氨酸。
(二).另外对融合蛋白的LHRH部分进行改造：
1.本专利将天然LHRH的N末端第一位的焦谷氨酸改为谷氨酸，然后将其与突变后的PE40进行融合连接，或者将突变了的LHRH与PE40进行融合连接，形成高亲和力融合蛋白。
2.本专利将一、中融合蛋白LHRH部分的N末端第6位突变为Ala或Trp或Leu。
(三).将LHRH或突变了的LHRH部分的N末端与毒素部分的C末端进行连接，并在LHRH或突变了的LHRH的C末端连接上XYEL或REDLK。
(四).将末尾含有XYEL或REDLK序列的融合蛋白末端序列XYEL或REDLK重复串联2-5次。
总结：对融合蛋白LHRH部分的突变使其对肿瘤细胞的亲和力增强；对融合蛋白毒素部分的改变使得融合蛋白的毒力增强；二个部分的同时改变使得融合蛋白的杀伤肿瘤细胞的活性更是大大增强。
四.具体实施方式
实例一
首先从cDNA文库中用PCR方法得到LHRH与PE40的基因片段。然后再用PCR与基因重组方法把融合蛋白PE40部分C末端5个氨基酸突变为KDEL，并获得重组基因载体pLHRH-PE40(KDEL)，对插入载体的基因片段LHRH-PE40(KDEL)进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，疏水层析和离子交换层析得到目的蛋白LHRH-PE40(KDEL)，用MTT细胞测活法测定LHRH-PE40(KDEL)的杀伤肿瘤细胞的活力。
此序列为LHRH-PE40(KDEL)(序列1)
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Lys-Asp-Glu-Leu
实例二
从pLHRH-PE40(KDEL)载体用PCR方法把融合蛋白PE40部分C末端4个氨基酸突变为RQEL，得到目的基因片段LHRH-PE40(RQEL)进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH-PE40(RQEL)，用MTT细胞测活法测定LHRH-PE40(RQEL)的杀伤肿瘤细胞的活力。
此序列为LHRH-PE40(RQEL)(序列2)
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Gln-Glu-Leu
实例三
从pLHRH-PE40(RQEL)载体用PCR方法把融合蛋白PE40部分C末端4个氨基酸突变为KEEL，得到目的基因片段LHRH-PE40(KEEL)进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH-PE40(KEEL)，用MTT细胞测活法测定LHRH-PE40(KEEL)的杀伤肿瘤细胞的活力。
此序列为LHRH-PE40(KEEL)(序列3)
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Lys-Glu-Glu-Leu
实例四
从pLHRH-PE40(KEEL)载体用PCR方法把融合蛋白PE40部分C末端4个氨基酸突变为REEL，得到目的基因片段LHRH-PE40(REEL)进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH-PE40(REEL)，用MTT细胞测活法测定LHRH-PE40(REEL)的杀伤肿瘤细胞的活力。
此序列为LHRH-PE40(REEL)(序列4)
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Glu-Leu
实例五
用PCR方法把融合蛋白PE40部分缺失氨基酸365-380部分，取其氨基酸254-364和氨基酸381-613部分按原顺序首尾相连得到的DNA序列即为蛋白PE38目的基因，然后对目的基因片段LHRH-PE38进行序列测定。验证其基因序列的正确性后，扩增保存，并把目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH-PE38，用MTT细胞测活法测定LHRH-PE38的杀伤肿瘤细胞的活力。
此序列为LHRH-PE38(序列5)
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys
实例六
用PCR方法把融合蛋白PE40部分缺失氨基酸253-279，365-380部分，取其氨基酸280-364和氨基酸381-613部分按原顺序首尾位相连得到的DNA序列即为蛋白PE35目的基因，对目的基因片段LHRH-PE35进行序列测定。验证其基因序列的正确性后，扩增保存，并把目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH-PE35，用MTT细胞测活法测定LHRH-PE35的杀伤肿瘤细胞的活力。
此序列为LHRH-PE35(序列6)
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys
实例七
从pLHRH-PE35载体用PCR方法把融合蛋白PE35部分C末端4个氨基酸突变为KDEL，得到目的基因片段LHRH-PE35(KDEL)进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH-PE35(KDEL)，用MTT细胞测活法测定LHRH-PE35(KDEL)的杀伤肿瘤细胞的活力。
此序列为LHRH-PE35(KDEL)(序列7)
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Lys-Asp-Glu-Leu
实例八
从pLHRH-PE40载体上，用PCR方法把融合蛋白LHRH部分N末端第6位氨基酸突变为Trp，得到目的基因片段LHRH(Trp6)-PE40进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH(Trp6)-PE40，用MTT细胞测活法测定LHRH(Trp6)-PE40的杀伤肿瘤细胞的活力。
此序列为LHRH(Trp6)-PE40(序列8)
Glu-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys
实例九
从LHRH(Trp6)-PE40载体用PCR方法把融合蛋白PE40部分C末端5个氨基酸突变为KDEL，得到目的基因片段LHRH(Trp6)-PE40(KDEL)进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH(Trp6)-PE40(KDEL)，用MTT细胞测活法测定LHRH(Trp6)-PE40(KDEL)的杀伤肿瘤细胞的活力。
此序列为LHRH(Trp6)-PE40(KDEL)(序列9)
Glu-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Lys-Asp-Glu-Leu
实例十
从pLHRH-PE38载体用PCR方法把融合蛋白LHRH部分N末端第6位氨基酸突变为Trp，得到目的基因片段LHRH(Trp6)-PE38进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH(Trp6)-PE38，用MTT细胞测活法测定LHRH(Trp6)-PE38的杀伤肿瘤细胞的活力。
此序列为LHRH(Trp6)-PE38(序列10)
Glu-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys
实例十一
从LHRH(Trp6)-PE38载体用PCR方法把融合蛋白PE38部分C末端5个氨基酸突变为KDEL，得到目的基因片段LHRH(Trp6)-PE38(KDEL)进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH(Trp6)-PE38(KDEL)，用MTT细胞测活法测定LHRH(Trp6)-PE38(KDEL)的杀伤肿瘤细胞的活力。
此序列为LHRH(Trp6)-PE38(KDEL)(序列11)
Glu-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Lys-Asp-Glu-Leu
实例十二
从pLHRH-PE35载体用PCR方法把融合蛋白LHRH部分N末端第6位氨基酸突变为Ala，得到目的基因片段LHRH(Ala6)-PE35进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH(Ala6)-PE35，用MTT细胞测活法测定LHRH(Ala6)-PE35的杀伤肿瘤细胞的活力。
此序列为LHRH(Ala6)-PE35(序列12)
Glu-His-Trp-Ser-Tyr-Ala-Leu-Arg-Pro-Gly-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys
实例十三
从LHRH(Ala6)-PE35载体用PCR方法把融合蛋白PE35部分C末端5个氨基酸突变为KDEL，得到目的基因片段LHRH(Ala6)-PE35(KDEL)进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH(Ala6)-PE35(KDEL)，用MTT细胞测活法测定LHRH(Ala6)-PE35(KDEL)的杀伤肿瘤细胞的活力。
此序列为LHRH(Ala6)-PE35(KDEL)(序列13)
Glu-His-Trp-Ser-Tyr-Ala-Leu-Arg-Pro-Gly-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Lys-Asp-Glu-Leu
实例十四
从LHRH(Ala6)-PE35载体用PCR方法把融合蛋白PE35部分C末端5个氨基酸突变为RQEL，得到目的基因片段LHRH(Ala6)-PE35(RQEL)进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH(Ala6)-PE35(RQEL)，用MTT细胞测活法测定LHRH(Ala6)-PE35(RQEL)的杀伤肿瘤细胞的活力。
此序列为LHRH(Ala6)-PE35(RQEL)(序列14)
Glu-His-Trp-Ser-Tyr-Ala-Leu-Arg-Pro-Gly-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Gln-Glu-Leu
实例十五
从cDNA文库中用PCR方法得到LHRH与PE40的基因片段后，用PCR与基因重组方法把PE40的C末端和LHRH的N末端相连，并在LHRH的C末端加上KDEL，获得重组基因载体pPE40-LHRH-KDEL，对插入载体的基因片段PE40-LHRH-KDEL进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白PE40-LHRH-KDEL，用MTT细胞测活法测定PE40-LHRH-KDEL的杀伤肿瘤细胞的活力。
此序列为PE40-LHRH-KDEL(序列15)
Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Lys-Asp-Glu-Leu
实例十六
从pPE40-LHRH-KDEL载体上，用PCR方法把融合蛋白PE40部分缺失氨基酸365-380部分，取其氨基酸254-364和氨基酸381-613部分及LHRH-KDEL部分按原顺序首尾相连得到得到目的基因片段PE38-LHRH-KDEL进行序列测定。验证其基因序列的正确性后，扩增保存，并把目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白PE38-LHRH-KDEL，用MTT细胞测活法测定PE38-LHRH-KDEL的杀伤肿瘤细胞的活力。
此序列为PE38-LHRH-KDEL(序列16)
Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Leu-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Lys-Asp-Glu-Leu
实例十七
从pPE40-LHRH-KDEL载体用PCR方法把融合蛋白PE40部分缺失氨基酸254-279，365-380部分，取其氨基酸280-364和氨基酸381-613部分及LHRH-KDEL按原顺序首尾位相连得到PE35-LHRH-KDEL进行序列测定。验证其基因序列的正确性后，扩增保存，并把目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白PE35-LHRH-KDEL，用MTT细胞测活法测定PE35-LHRH-KDEL的杀伤肿瘤细胞的活力。
此序列为PE35-LHRH-KDEL(序列17)
Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Lys-Asp-Glu-Leu
实例十八
从pPE35-LHRH-KDEL载体上，用PCR方法把融合蛋白C末端4个氨基酸突变为REDLK，得到目的基因片段PE35-LHRH-REDLK进行序列测定。验证其基因序列的正确性后，扩增保存，并把目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白PE35-LHRH-REDLK，用MTT细胞测活法测定PE35-LHRH-REDLK的杀伤肿瘤细胞的活力。
此序列为PE35-LHRH-REDLK(序列18)
Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Arg-Glu-Asp-Leu-Lys
实例十九
从pPE40-LHRH-KDEL载体用PCR方法把融合蛋白LHRH部分N末端第6位氨基酸突变为Trp，得到目的基因片段PE40-LHRH(Trp6)-KDEL进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白PE40-LHRH(Trp6)-KDEL，用MTT细胞测活法测定PE40-LHRH(Trp6)-KDEL的杀伤肿瘤细胞的活力。
此序列为PE40-LHRH(Trp6)-KDEL(序列19)
Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys-Glu-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-Lys-Asp-Glu-Leu
实例二十
从pPE35-LHRH-KDEL载体上，用PCR方法把融合蛋白LHRH部分N末端第6位氨基酸突变为Ala，得到目的基因片段PE35-LHRH(Ala6)-KDEL进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白PE35-LHRH(Ala6)-KDEL，用MTT细胞测活法测定PE35-LHRH(Ala6)-KDEL的杀伤肿瘤细胞的活力。
此序列为PE35-LHRH(Ala6)-KDEL(序列20)
Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys-Glu-His-Trp-Ser-Tyr-Ala-Leu-Arg-Pro-Gly-Lys-Asp-Glu-Leu
实例二十一
从pPE40-LHRH(Trp6)-KDEL载体上，用PCR方法把融合蛋白C末端4个氨基酸突变为REDLK，得到目的基因片段PE40-LHRH(Trp6)-REDLK进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白PE40-LHRH(Trp6)-REDLK用MTT细胞测活法测定PE40-LHRH(Trp6)-REDLK的杀伤肿瘤细胞的活力。
此序列为PE40-LHRH(Trp6)-REDLK(序列21)
Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys-Glu-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-Arg-Glu-Asp-Leu-Lys
实例二十二
从pPE35-LHRH(Ala6)-KDEL载体上，用PCR方法把融合蛋白C末端4个氨基酸突变为REDLK，得到目的基因片段PE35-LHRH(Ala6)-REDLK进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白PE35-LHRH(Ala6)-REDLK，用MTT细胞测活法测定PE35-LHRH(Ala6)-REDLK的杀伤肿瘤细胞的活力。
此序列为PE35-LHRH(Ala6)-REDLK(序列22)
Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys-Glu-His-Trp-Ser-Tyr-Ala-Leu-Arg-Pro-Gly-Arg-Glu-Asp-Leu-Lys
实例二十三
从pLHRH-PE40载体上，用PCR方法把融合蛋白PE40部分C末端5个氨基酸突变为KDELKDELKDEL，得到目的基因片段LHRH-PE40-KDELKDELKDEL进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH-PE40-KDELKDELKDEL，用MTT细胞测活法测定LHRH-PE40-KDELKDELKDEL的杀伤肿瘤细胞的活力。
此序列为LHRH-PE40-KDELKDELKDEL(序列23)
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Lys-Asp-Glu-Leu-Lys-Asp-Glu-Leu-Lys-Asp-Glu-Leu
实例二十四
从pLHRH-PE40-KDELKDELKDEL载体上，用PCR方法把融合蛋白LHRH部分N末端第6位氨基酸突变为Trp，得到目的基因片段LHRH(Trp6)-PE40-KDELKDELKDEL进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH(Trp6)-PE40-KDELKDELKDEL，用MTT细胞测活法测定LHRH(Trp6)-PE40-KDELKDELKDEL的杀伤肿瘤细胞的活力。
此序列为LHRH(Trp6)-PE40-KDELKDELKDEL(序列24)
Glu-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Se-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Lys-Asp-Glu-Leu-Lys-Asp-Glu-Leu-Lys-Asp-Glu-Leu
实例二十五
从pLHRH-PE35载体上，用PCR方法把融合蛋白PE35部分C末端5个氨基酸突变为KDELKDELKDEL，得到目的基因片段LHRH-PE35-KDELKDELKDEL进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH-PE35-KDELKDELKDEL，用MTT细胞测活法测定LHRH-PE35-KDELKDELKDEL的杀伤肿瘤细胞的活力。
此序列为LHRH-PE35-KDELKDELKDEL(序列25)
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Lys-Asp-Glu-Leu-Lys-Asp-Glu-Leu-Lys-Asp-Glu-Leu
实例二十六
从pLHRH-PE35-KDELKDELKDEL载体用PCR方法把融合蛋白LHRH部分N末端第6个氨基酸突变为Ala，得到目的基因片段LHRH(Ala6)-PE35-KDELKDELKDEL进行序列测定。验证其基因序列的正确性后，扩增保存，从该载体上切取下目的基因片段，插入表达载体中，再把重组表达载体导入表达宿主菌中，经培养表达，纯化得到目的蛋白LHRH(Ala6)-PE35-KDELKDELKDEL，用MTT细胞测活法测定LHRH(Ala6)-PE35-KDELKDELKDEL的杀伤肿瘤细胞的活力。
此序列为LHRH(Ala6)-PE35-KDELKDELKDEL(序列26)
Glu-His-Trp-Ser-Tyr-Ala-Leu-Arg-Pro-Gly-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Lys-Asp-Glu-Leu-Lys-Asp-Glu-Leu-Lys-Asp-Glu-Leu
实例二十七
用MTT比色法测定细胞增殖中活细胞的数目，以此确定融合蛋白的杀伤各种肿瘤细胞的活力，所选的肿瘤细胞包括SPC(人肺腺癌细胞)、HL60(人白血病细胞)、MGC(人胃癌细胞)、PC-3(人前列腺癌细胞)和MCF-7(人乳腺癌细胞)。取96孔细胞培养板3块，每孔接种细胞数为1×104、每块培养板每种细胞重复接种20个孔，37℃、5％CO2条件下培养，然后分别加入等比稀释融合蛋白样品，接着培养24，48及72h后，每孔加5g/L MTT 20μl再培养4h，然后去上清液加入二甲亚砜200μl，将培养板放在微量振荡器上振荡10min，待MTT被细胞还原形成甲颗粒完全溶解后，立即用酶标仪、波长570nm测定其吸光度，然后通过标准计算公式计算出目的蛋白活性。上述实验重复3次，计算其平均IC50值。
结果：见表1，以LHRH-PE40为对照，实例1-7中融合蛋白突变体是单独对PE40部分进行的突变，活性大约提高了5-20倍；实例8中的融合蛋白突变体是单独对LHRH部分进行的突变，活性提高了10倍；实例9-14中的融合蛋白突变体是结合了LHRH和PE40部分二者的突变体，活性提高了50-1000倍；实例15-22中的融合蛋白突变体活性提高了20-500倍；实例22-26中的融合蛋白突变体活性提高了100-800倍。
表1.实例中的融合蛋白细胞活性
  序号   细胞IC50融合蛋白   SPC(ug/mL)   HL60(ug/mL)   MGC(ug/mL)   PC-3(ug/mL)   MCF-7(ug/mL)
  0   LHRH-PE40   28.2   19.8   52.1   2.75   1.48
  1   LHRH-PE40(KDEL)   6.8   15.4   20.1   0.58   0.54
  2   LHRH-PE40(RQEL)   10.7   19.1   16.7   1.3   0.48
  3   LHRH-PE40(KEEL)   8.2   22.4   21.2   0.86   0.62
  4   LHRH-PE40(REEL)   7.6   15.7   18.3   1.2   0.37
  5   LHRH-PE38   3.2   2.4   4.3   0.25   0.22
  6   LHRH-PE35   2.1   1.3   6.8   0.18   0.25
  7   LHRH-PE35(KDEL)   1.5   1.4   2.6   0.14   0.12
  8   LHRH(Trp6)-PE40   3.1   2.1   5.3   0.28   0.16
  9   LHRH(Trp6)-PE40(KDEL)   1.1   1.8   1.2   0.061   0.032
  10   LHRH(Trp6)-PE38   0.24   0.28   0.66   0.019   0.022
  11   LHRH(Trp6)-PE38(KDEL)   0.062   0.055   0.17   0.0052   0.0038
  12   LHRH(Ala6)-PE35   0.18   0.22   0.74   0.057   0.041
  13   LHRH(Ala6)-PE35(KDEL)   0.022   0.025   0.48   0.0013   0.0021
  14   LHRH(Ala6)-PE35(RQEL)   0.046   0.032   0.28   0.0037   0.0018
  15   PE40-LHRH-KDEL   2.6   1.4   3.9   0.17   0.048
  16   PE38-LHRH-KDEL   2.2   0.65   2.8   0.095   0.041
  17   PE35-LHRH-KDEL   3.41   0.66   2.2   0.11   0.026
  18   PE35-LHRH-REDLK   2.7   0.42   1.9   0.074   0.023
  19   PE40-LHRH(Trp6)-KDEL   0.12   0.077   0.22   0.012   0.0052
  20   PE35-LHRH(Ala6)-KDEL   0.074   0.041   0.16   0.0071   0.0022
  21   PE40-LHRH(Trp6)-REDLK   0.33   0.35   0.69   0.26   0.21
  22   PE35-LHRH(Ala6)-REDLK   0.062   0.081   0.14   0.044   0.022
  23   LHRH-PE40(KDEL)3   0.41   0.16   0.32   0.35   0.16
  24   LHRH(Trp6)-PE40(KDEL)3   0.085   0.055   0.062   0.077   0.043
  25   LHRH(Ala6)-PE35(KDEL)3   0.022   0.031   0.064   0.0018   0.0011
五.序列表
(1)序列1
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-(Lys-Asp-Glu-Leu)n
说明：该序列的N末端第6位Gly可替换成为Ala、Trp或Leu；该序列的C末端第3位Asp可替换成Gln或Glu；该序列C末端第4位Lys可替换成Arg。n小于等于5大于等于1。并且该序列C末端的氨基酸-(Lys-Asp-Glu-Leu)n可替换成-(Arg-Glu-Asp-Leu-Lys)n，n小于等于5大于等于1。
(2)序列2
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Gly-Ser-Leu-Ala-Ala-Leu-Thr-Ala-His-Gln-Ala-Cys-His-Leu-Pro-Leu-Glu-Thr-Phe-Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-(Lys-Asp-Glu-Leu)n
说明：该序列的N末端第6位Gly可替换成为Ala、Trp或Leu；该序列的C末端第3位Asp可替换成Gln或Glu；该序列C末端第4位Lys可替换成Arg。n小于等于5大于等于1。并且该序列C末端的氨基酸-(Lys-Asp-Glu-Leu)n可替换成-(Arg-Glu-Asp-Leu-Lys)n，n小于等于5大于等于1。
(3)序列3
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-(Lys-Asp-Glu-Leu)n
说明：该序列的N末端第6位Gly可替换成为Ala、Trp或Leu；该序列的C末端第3位Asp可替换成Gln或Glu；该序列C末端第4位Lys可替换成Arg。n小于等于5大于等于1。并且该序列C末端的氨基酸-(Lys-Asp-Glu-Leu)n可替换成-(Arg-Glu-Asp-Leu-Lys)n，n小于等于5大于等于1。
(4)序列4
Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Ala-Asp-Val-Val-Ser-Leu-Thr-Cys-Pro-Val-Ala-Ala-Gly-Glu-Cys-Ala-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-(Lys-Asp-Glu-Leu)n
说明：该序列的N末端第6位Gly可替换成为Ala、Trp或Leu；该序列的C末端第3位Asp可替换成Gln或Glu；该序列C末端第4位Lys可替换成Arg；n小于等于5大于等于1。并且该序列C末端的氨基酸-(Lys-Asp-Glu-Leu)n可替换成-(Arg-Glu-Asp-Leu-Lys)n，n小于等于5大于等于1。
(5)序列5
Gly-Trp-Glu-Gln-Leu-Glu-Gln-Cys-Gly-Tyr-Pro-Val-Gln-Arg-Leu-Val-Ala-Leu-Tyr-Leu-Ala-Ala-Arg-Leu-Ser-Trp-Asn-Gln-Val-Asp-Gln-Val-Ile-Arg-Asn-Ala-Leu-Ala-Ser-Pro-Gly-Ser-Gly-Gly-Asp-Leu-Gly-Glu-Ala-Ile-Arg-Glu-Gln-Pro-Glu-Gln-Ala-Arg-Leu-Ala-Leu-Thr-Leu-Ala-Ala-Ala-Glu-Ser-Glu-Arg-Phe-Val-Arg-Gln-Gly-Thr-Gly-Asn-Asp-Glu-Ala-Gly-Ala-Ala-Asn-Gly-Pro-Ala-Asp-Ser-Gly-Asp-Ala-Leu-Leu-Glu-Arg-Asn-Tyr-Pro-Thr-Gly-Ala-Glu-Phe-Leu-Gly-Asp-Gly-Gly-Asp-Val-Ser-Phe-Ser-Thr-Arg-Gly-Thr-Gln-Asn-Trp-Thr-Val-Glu-Arg-Leu-Leu-Gln-Ala-His-Arg-Gln-Leu-Glu-Glu-Arg-Gly-Tyr-Val-Phe-Val-Gly-Tyr-His-Gly-Thr-Phe-Leu-Glu-Ala-Ala-Gln-Ser-Ile-Val-Phe-Gly-Gly-Val-Arg-Ala-Arg-Ser-Gln-Asp-Leu-Asp-Ala-Ile-Trp-Arg-Gly-Phe-Tyr-Ile-Ala-Gly-Asp-Pro-Ala-Leu-Ala-Tyr-Gly-Tyr-Ala-Gln-Asp-Gln-Glu-Pro-Asp-Ala-Arg-Gly-Arg-Ile-Arg-Asn-Gly-Ala-Leu-Leu-Arg-Val-Tyr-Val-Pro-Arg-Ser-Ser-Leu-Pro-Gly-Phe-Tyr-Arg-Thr-Ser-Leu-Thr-Leu-Ala-Ala-Pro-Glu-Ala-Ala-Gly-Glu-Val-Glu-Arg-Leu-Ile-Gly-His-Pro-Leu-Pro-Leu-Arg-Leu-Asp-Ala-Ile-Thr-Gly-Pro-Glu-Glu-Glu-Gly-Gly-Arg-Leu-Glu-Thr-Ile-Leu-Gly-Trp-Pro-Leu-Ala-Glu-Arg-Thr-Val-Val-Ile-Pro-Ser-Ala-Ile-Pro-Thr-Asp-Pro-Arg-Asn-Val-Gly-Gly-Asp-Leu-Asp-Pro-Ser-Ser-Ile-Pro-Asp-Lys-Glu-Gln-Ala-Ile-Ser-Ala-Leu-Pro-Asp-Tyr-Ala-Ser-Gln-Pro-Gly-Lys-Pro-Pro-Arg-Glu-Asp-Leu-Lys-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-(Lys-Asp-Glu-Leu)n
说明：该序列的C末端第9位Gly可替换成为Ala、Trp或Leu；该序列的C末端第3位Asp可替换成Gln或Glu；该序列C末端第4位Lys可替换成Arg；n小于等于5大于等于1。并且该序列C末端的氨基酸-(Lys-Asp-Glu-Leu)n可替换成-(Arg-Glu-Asp-Leu-Lys)n，n小于等于5大于等于1。

Claims (11)

1.一种基因工程重组融合蛋白，其特征是由氨基末端第一位氨基酸替换成谷氨酸(Glu)的天然人促黄体生成激素释放因子(LHRH)和假单胞菌外毒素A的缺失体PE40的多种突变体的一种串联组成的融合蛋白；或者由氨基末端第一位氨基酸替换成谷氨酸(Glu)的天然人促黄体生成激素释放因子氨基末端第6位突变为丙氨酸(Ala)或色氨酸(Trp)或亮氨酸(Leu)的突变体和PE40及其多种突变体的一种串联组成的融合蛋白，上述发明的融合蛋白与LHRH-PE40相比具有更强的特异性杀伤肿瘤细胞的特性。
2.根据权利要求1所说的基因工程重组融合蛋白，其特征是：该融合蛋白是由氨基末端第一位氨基酸突变替换成谷氨酸(Glu)的天然人促黄体生成激素释放因子或其突变体的蛋白C末端与假单胞菌外毒素A的PE40部分或其突变体的氨基末端相连，其结构特征为：M-N，M代表氨基末端第一位氨基酸替换成谷氨酸(Glu)的天然人促黄体生成激素释放因子及其氨基末端第6位突变为Ala或Trp或Leu的突变体；N代表PE40及其多种突变体，并且M、N之间通过肽键连接。
3.根据权利要求1或2所述的基因工程重组融合蛋白，其特征是：该融合蛋白的PE40部分的突变体包括将PE40的C末端5个氨基酸置换为XYEL，其中X代表赖氨酸(Lys)或精氨酸(Arg)，Y代表天冬氨酸(Asp)，谷氨酰胺(Gln)或谷氨酸(Glu)，E代表谷氨酸(Glu)，L代表亮氨酸(Leu)。
4.根据权利要求1或2所述的基因工程重组融合蛋白，其特征是：该融合蛋白的PE40部分的突变体包括取假单胞杆菌外毒素A的253-364，381-613两段氨基酸序列按原顺序相连得到蛋白PE38。
5.根据权利要求4所述的基因工程重组融合蛋白，其特征是：该融合蛋白的PE40部分的突变体包括将PE38的C末端5个氨基酸置换为XYEL，其中X代表赖氨酸(Lys)或精氨酸(Arg)，Y代表天冬氨酸(Asp)，谷氨酰胺(Gln)或谷氨酸(Glu)，E代表谷氨酸(Glu)，L代表亮氨酸(Leu)。
6.根据权利要求1或2所述的基因工程重组融合蛋白，其特征是：该融合蛋白的PE40部分的突变体包括取假单胞杆菌外毒素A的280-364，381-613两段氨基酸序列按原顺序相连得到蛋白PE35。
7.根据权利要求6所述的基因工程重组融合蛋白，其特征是：该融合蛋白的PE40部分的突变体包括将PE35的C末端5个氨基酸置换为XYEL，其中X代表赖氨酸(Lys)或精氨酸(Arg)，Y代表天冬氨酸(Asp)，谷氨酰胺(Gln)或谷氨酸(Glu)，E代表谷氨酸(Glu)，L代表亮氨酸(Leu)。
8.根据权利要求1或2所述的基因工程重组融合蛋白，其特征是：该融合蛋白的PE40部分的突变体包括取假单胞杆菌外毒素A的280-613部分氨基酸序列得到蛋白PE37。
9.根据权利要求8所述的基因工程重组融合蛋白，其特征是：该融合蛋白的PE40部分的突变体包括将PE37的C末端5个氨基酸置换为XYEL，其中X代表赖氨酸(Lys)或精氨酸(Arg)，Y代表天冬氨酸(Asp)，谷氨酰胺(Gln)或谷氨酸(Glu)，E代表谷氨酸(Glu)，L代表亮氨酸(Leu)。
10.根据权利要求2所述的基因工程重组融合蛋白，其特征是：组成该融合蛋白的两种单一蛋白间连接顺序改变，即M-N变为N-M，同时，在该融合蛋白C末端连上氨基酸序列XYEL或REDLK，即N-M-XYEL或N-M-REDLK，其中X代表赖氨酸(Lys)或精氨酸(Arg)，Y代表天冬氨酸(Asp)，谷氨酰胺(Gln)或谷氨酸(Glu)，E代表谷氨酸(Glu)，L代表亮氨酸(Leu)，R代表精氨酸(Arg)，D代表天冬氨酸(Asp)，K代表赖氨酸(Lys)。
11.根据权利要求10所述的基因工程重组融合蛋白，其特征是：将该融合蛋白序列C末端XYEL或REDLK片段重复串连2-5次，即M-N-(XYEL)n、M-N-(REDLK)n、N-M-(XYEL)n、N-M-(REDLK)n，其中n≤5，其中X代表赖氨酸(Lys)或精氨酸(Arg)，Y代表天冬氨酸(Asp)，谷氨酰胺(Gln)或谷氨酸(Glu)，E代表谷氨酸(Glu)，L代表亮氨酸(Leu)，R代表精氨酸(Arg)，D代表天冬氨酸(Asp)，K代表赖氨酸(Lys)。
CN 03137587 2003-06-18 2003-06-18 一种能特异杀死肿瘤细胞的基因工程重组蛋白 Expired - Lifetime CN1294149C (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 03137587 CN1294149C (zh) 2003-06-18 2003-06-18 一种能特异杀死肿瘤细胞的基因工程重组蛋白

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 03137587 CN1294149C (zh) 2003-06-18 2003-06-18 一种能特异杀死肿瘤细胞的基因工程重组蛋白

Publications (2)

Publication Number Publication Date
CN1566159A CN1566159A (zh) 2005-01-19
CN1294149C true CN1294149C (zh) 2007-01-10

Family

ID=34470457

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 03137587 Expired - Lifetime CN1294149C (zh) 2003-06-18 2003-06-18 一种能特异杀死肿瘤细胞的基因工程重组蛋白

Country Status (1)

Country Link
CN (1) CN1294149C (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1768862A (zh) * 2004-10-26 2006-05-10 北京诺思兰德生物技术有限责任公司 一类能与表达GnRH受体的癌细胞特异结合且用锝－99m标记的蛋白
CN101195822B (zh) * 2006-12-08 2012-08-08 湖南康都制药有限公司 高亲和性靶向融合蛋白
CN101433713B (zh) * 2007-11-15 2011-10-12 北京诺思兰德生物技术股份有限公司 GnRH-PE突变体融合蛋白及其用途
CN103864938A (zh) * 2014-03-24 2014-06-18 北京博翱泰生物技术有限公司 靶特异性双突变体融合蛋白质及其制备工艺

Also Published As

Publication number Publication date
CN1566159A (zh) 2005-01-19

Similar Documents

Publication Publication Date Title
CN1236370A (zh) 化学修饰的多肽
CN1165539A (zh) 肽及蛋白质的修饰
CN1646702A (zh) 用于治疗性寡核苷酸的蛋白质载体系统
CN1853730A (zh) 用于治疗癌症的修饰细胞因子
CN1294149C (zh) 一种能特异杀死肿瘤细胞的基因工程重组蛋白
CN1654656A (zh) 中国明对虾Crustin基因和编码蛋白及其克隆方法
CN1786165A (zh) 重组金黄色葡萄球菌肠毒素c2的制备方法
CN1861790A (zh) 重组人甲状旁腺激素1－84的制备方法
CN100341897C (zh) 肿瘤新生血管特异性结合多肽CRGDC与新型重组人肿瘤坏死因子nrhTNF融合蛋白及制备方法
CN1264861C (zh) 带有接头序列的受体导向性嵌合毒素
CN1687119A (zh) 表皮生长因子受体靶向短肽与力达霉素构成的抗肿瘤基因工程融合蛋白
CN1900119A (zh) 金黄色葡萄球菌肠毒素i及制备和应用
CN1263598A (zh) 对外来火蚁有特异性的抗体和scfv免疫毒素及其应用
CN101061136A (zh) 具有白介素－2中和能力的免疫治疗制剂
CN1238378C (zh) 一种抗菌肽及其编码序列和用途
CN1506375A (zh) 具有广谱抗肿瘤作用的细菌蛋白天青蛋白及其用途和含有其的药物组合物
CN1279058C (zh) 用于诱导白血病细胞分化及凋亡的抗cd44的工程抗体及其载体和用途
CN1232532C (zh) 成纤维细胞生长因子－2结构类似物,其生产方法及应用
CN1289527C (zh) 一种高生物活性的角质细胞生长因子突变体，其制备方法及用途
CN110078812A (zh) 多肽imb-m2的异源表达及其在增强nk细胞杀瘤活性中的应用
CN1827649A (zh) 新的融合毒素蛋白质及其应用
CN101066993A (zh) 重组金黄色葡萄球菌肠毒素m及制备和应用
CN1228451C (zh) 肿瘤多药耐药性逆转药物筛选新方法
CN1869230A (zh) 一种人白细胞介素21的核苷酸序列及生产成熟的人白细胞介素21的方法和应用
CN1169835C (zh) 人b淋巴细胞刺激因子突变体及其构建方法和编码基因

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BEIJING NORTHLAND BIOTECHNOLOGY LIMITED LIABILITY

Free format text: FORMER OWNER: LI XIANGZHE

Effective date: 20060317

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060317

Address after: 100085 A402 room, No. 5, Pioneer Road, Beijing, Haidian District

Applicant after: BEIJING NORTHLAND BIOTECH Co.,Ltd.

Address before: 100086 A607 room, No. 113 silver net center, Zhichun Road, Haidian District, Beijing

Applicant before: Li Xiangzhe

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: BEIJING NUOSILANDE BIOTECHNOLOGY CO., LTD.

Free format text: FORMER NAME: BEIJING NORTHLAND BIOTECHNOLOGY LIMITED LIABILITY COMPANY

CP01 Change in the name or title of a patent holder

Address after: Room A402, No. 5, Pioneer Road, Beijing, Haidian District

Patentee after: BEIJING NORTHLAND BIOTECH. Co.,Ltd.

Address before: Room A402, No. 5, Pioneer Road, Beijing, Haidian District

Patentee before: BEIJING NORTHLAND BIOTECH Co.,Ltd.

EE01 Entry into force of recordation of patent licensing contract

Assignee: TIANJIN TOPTECH BIO-SCIENCE & TECHNOLOGY Co.,Ltd.

Assignor: BEIJING NORTHLAND BIOTECH. Co.,Ltd.

Contract record no.: 2010120000102

Denomination of invention: Genet engineering recombinant protein capable of specifically killing tumor cell

Granted publication date: 20070110

License type: Exclusive License

Open date: 20050119

Record date: 20100817

EC01 Cancellation of recordation of patent licensing contract

Assignee: TIANJIN TOPTECH BIO-SCIENCE & TECHNOLOGY Co.,Ltd.

Assignor: BEIJING NORTHLAND BIOTECH. Co.,Ltd.

Contract record no.: 2010120000102

Date of cancellation: 20131211

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20050119

Assignee: BEIJING HUONLAND PHARMACEUTICAL Co.,Ltd.

Assignor: BEIJING NORTHLAND BIOTECH. Co.,Ltd.

Contract record no.: 2015110000002

Denomination of invention: Genet engineering recombinant protein capable of specifically killing tumor cell

Granted publication date: 20070110

License type: Exclusive License

Record date: 20150206

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20070110